NECFA
RAPT

New England Capital Financial Advisors’s RAPT Therapeutics RAPT Stock Holding History

New England Capital Financial Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-125
Closed -$18.4K – 426
2023
Q1 		$18.4K Hold
125
– – 0.01% 185
2022
Q4 		$28.2K Buy
+125
New +$20K 0.02% 157

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

New England Capital Financial Advisors's RAPT Position: Q2 2023 in Review

New England Capital Financial Advisors sold out of RAPT Therapeutics (RAPT) in Q2 2023, closing a stake of 125 shares — an estimated $18.4K sold.

New England Capital Financial Advisors first reported a position in RAPT in Q4 2022 and held it in 2 quarters. The position peaked at $28.2K in Q4 2022. 98 funds tracked by Wall St. Rank hold RAPT as of Q2 2023.

  • New England Capital Financial Advisors reported no remaining RAPT Therapeutics position as of Q2 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 125 RAPT Therapeutics shares in Q2 2023, an estimated $18.4K.
  • New England Capital Financial Advisors first reported a position in RAPT Therapeutics in Q4 2022 and held it in 2 quarters.
  • New England Capital Financial Advisors's RAPT Therapeutics position peaked at $28.2K in Q4 2022.
  • 98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2023.

Based on New England Capital Financial Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.